Recently, Biomarck Pharmaceuticals, Ltd.announced the a Phase 2a clinical results of BIO-11006 for patients with ARDS (Acute Respiratory Distress Syndrome). The 38-patient study met the primary endpoint of no significant increase in serious adverse events, and reduced all-cause mortality from ARDS at 28 days.BIO-11006 is the 10 amino acid N-terminal of MARCKS protein that inhibits the pro-inflammatory effects of overactive MARCKS protein. For more information please visit: https://clinicaltrials.gov: Identifier (NCT03202394).
Acute Respiratory Distress Syndrome
Globally, ARDS affects over 3 million people a year. ARDS is a life-threatening condition causing widespread capillary leakage and inflammation of the lungs. Breathing becomes difficult and oxygen cannot get into the body. ARDS can be caused by a variety of insults including bacterial and viral pneumonia, sepsis, smoke inhalation, aspiration, and, most recently, the novel COVID-19 virus. Treatment options for ARDS are limited beyond mechanical ventilation, and approximately 40 percent of ARDS patients do not survive.